Výsledky vyhledávání - "Paul (A.) Beavis"

Akademický článek

Pharmacologic inhibition of dipeptidyl peptidase 1 (cathepsin C) does not block in vitro granzyme-mediated target cell killing by CD8 T or NK cells

Autor: Vivien R. Sutton, Sally V. Watt, Hedieh Akhlaghi, David C. Cipolla, Kuan-Ju Chen, Daniel LaSala, Patrick P. McDonald, Paul A. Beavis, Isabelle Munoz, Adrian W. Hodel, Tahereh Noori, Ilia Voskoboinik, Joseph A. Trapani

Publikováno v: Frontiers in Pharmacology, Vol 15 (2024)

Recently developed small-molecule inhibitors of the lysosomal protease dipeptidyl peptidase 1 (DPP1), also known as cathepsin C (CatC), can suppress suppurative inflammation in vivo by blocking the processing of zymogenic (pro-) forms of neutrophil s

Externí odkaz: https://doaj.org/article/637ceae3f9ef4a27add5a0ac7f8e1bc1

Zobrazit plný text záznamu

Akademický článek

A2AR eGFP reporter mouse enables elucidation of A2AR expression dynamics during anti-tumor immune responses

Publikováno v: Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)

Abstract There is significant clinical interest in targeting adenosine-mediated immunosuppression, with several small molecule inhibitors having been developed for targeting the A2AR receptor. Understanding of the mechanism by which A2AR is regulated

Externí odkaz: https://doaj.org/article/b9c76314c12142099494e8759d06a025

Zobrazit plný text záznamu

Akademický článek

CRISPR-Cas9 screening identifies an IRF1-SOCS1-mediated negative feedback loop that limits CXCL9 expression and antitumor immunity

Publikováno v: Cell Reports, Vol 42, Iss 8, Pp 113014- (2023)

Summary: CXCL9 expression is a strong predictor of response to immune checkpoint blockade therapy. Accordingly, we sought to develop therapeutic strategies to enhance the expression of CXCL9 and augment antitumor immunity. To perform whole-genome CRI

Externí odkaz: https://doaj.org/article/36f8c10bf54b436e8b3737f736a4464b

Zobrazit plný text záznamu

Akademický článek

Differential location of NKT and MAIT cells within lymphoid tissue

Autor: Darryl N. Johnson, Zheng Ruan, Emma V. Petley, Sapna Devi, Lauren E. Holz, Adam P. Uldrich, Jeffrey Y. W. Mak, Jyh Liang Hor, Scott N. Mueller, James McCluskey, David P. Fairlie, Phillip K. Darcy, Paul A. Beavis, William R. Heath, Dale I. Godfrey

Publikováno v: Scientific Reports, Vol 12, Iss 1, Pp 1-22 (2022)

Abstract Natural Killer T (NKT) cells and Mucosal-Associated Invariant T (MAIT) cells are innate-like T cells that express semi-invariant αβ T cell receptors (TCRs) through which they recognise CD1d and MR1 molecules, respectively, in complex with

Externí odkaz: https://doaj.org/article/752fb81bb7254b64a74120356ca7f38e

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

MAIT cells regulate NK cell-mediated tumor immunity

Publikováno v: Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)

Mucosal-associated invariant T (MAIT) cells facilitate anti-microbial responses, but their functions in cancer protection is unclear. Here the authors show that activated MAIT cells induce an IFN-γ transcriptome in natural killer (NK) cells and enha

Externí odkaz: https://doaj.org/article/01f893fc7b8b403cadf95ab8ec274a3e

Zobrazit plný text záznamu

Akademický článek

The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells

Autor: Kelden Richardson, Simon P. Keam, Joe Jiang Zhu, Deborah Meyran, Criselle D’Souza, Sean Macdonald, Kerry Campbell, Michael Robbins, Natalie A. Bezman, Kirsten Todd, Hang Quach, David S. Ritchie, Simon J. Harrison, H. Miles Prince, Joseph A. Trapani, Misty R. Jenkins, Paul A. Beavis, Phillip K. Darcy, Paul J. Neeson

Publikováno v: Haematologica, Vol 108, Iss 1 (2022)

Patients with refractory relapsed multiple myeloma respond to combination treatment with elotuzumab and lenalidomide. The mechanisms underlying this observation are not fully understood. Furthermore, biomarkers predictive of response have not been id

Externí odkaz: https://doaj.org/article/330bde42af204d128415d365b42720c4

Zobrazit plný text záznamu

Akademický článek

CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy

Autor: Lauren Giuffrida, Kevin Sek, Melissa A. Henderson, Junyun Lai, Amanda X. Y. Chen, Deborah Meyran, Kirsten L. Todd, Emma V. Petley, Sherly Mardiana, Christina Mølck, Gregory D. Stewart, Benjamin J. Solomon, Ian A. Parish, Paul J. Neeson, Simon J. Harrison, Lev M. Kats, Imran G. House, Phillip K. Darcy, Paul A. Beavis

Publikováno v: Nature Communications, Vol 12, Iss 1, Pp 1-18 (2021)

Activation of the adenosine receptor A2AR is associated with suppression of T cell function in the tumor microenvironment. To overcome immunosuppression, here the authors show that CRISPR/Cas9 mediated deletion of A2AR enhances CAR T cell effector fu

Externí odkaz: https://doaj.org/article/483b1c1b715b445cad3cbef377ef8466

Zobrazit plný text záznamu

Akademický článek

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

Autor: Sathana Dushyanthen, Zhi Ling Teo, Franco Caramia, Peter Savas, Christopher P. Mintoff, Balaji Virassamy, Melissa A. Henderson, Stephen J. Luen, Mariam Mansour, Michael H. Kershaw, Joseph A. Trapani, Paul J. Neeson, Roberto Salgado, Grant A. McArthur, Justin M. Balko, Paul A. Beavis, Phillip K. Darcy, Sherene Loi

Publikováno v: Nature Communications, Vol 8, Iss 1, Pp 1-18 (2017)

MEK inhibition in breast cancer is associated with increased tumour infiltrating lymphocytes (TILs), however, MAPK activity is required for T cells function. Here the authors show that TILs activity following MEK inhibition can be enhanced by agonist

Externí odkaz: https://doaj.org/article/9dca7cf8454b4a3b9462fc4df89bf7de

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání